The Future of Cardiac Magnetic Resonance Clinical Trials

JACC Cardiovasc Imaging. 2022 Dec;15(12):2127-2138. doi: 10.1016/j.jcmg.2021.07.029. Epub 2021 Dec 15.

Abstract

Over the past 2 decades, cardiac magnetic resonance (CMR) has become an essential component of cardiovascular clinical care and contributed to imaging-guided diagnosis and management of coronary artery disease, cardiomyopathy, congenital heart disease, cardio-oncology, valvular, and vascular disease, amongst others. The widespread availability, safety, and capability of CMR to provide corresponding anatomical, physiological, and functional data in 1 imaging session can improve the design and conduct of clinical trials through both a reduction of sample size and provision of important mechanistic data that may augment clinical trial findings. Moreover, prospective imaging-guided strategies using CMR can enhance safety, efficacy, and cost-effectiveness of cardiovascular pathways in clinical practice around the world. As the future of large-scale clinical trial design evolves to integrate personalized medicine, cost-effectiveness, and mechanistic insights of novel therapies, the integration of CMR will continue to play a critical role. In this document, the attributes, limitations, and challenges of CMR's integration into the future design and conduct of clinical trials will also be covered, and recommendations for trialists will be explored. Several prominent examples of clinical trials that test the efficacy of CMR-imaging guided pathways will also be discussed.

Keywords: cardiac magnetic resonance; clinical trials.

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Magnetic Resonance Spectroscopy
  • Predictive Value of Tests
  • Prospective Studies*